Literature DB >> 10086236

Fine-needle aspiration cytology and immunocytochemistry of soft-tissue tumors and osteo/chondrosarcomas of the head and neck.

L Skoog1, S T Pereira, E Tani.   

Abstract

The purpose of the study was to present the clinical and cytological findings of 28 cases of malignant or borderline mesenchymal tumors of the head and neck, of which 22 originated from soft tissue and 6 were found in bone or cartilage. The basic procedures employed involved a cytologic review and subclassification of fine-needle aspiration (FNA) smears from the tumors, which were diagnosed as: pleomorphic sarcomas (5 poorly differentiated, 1 angiosarcoma, and 1 epithelioid sarcoma), spindle-cell sarcomas (2 leiomyosarcomas, 2 malignant mesenchymal tumors, and 1 malignant schwannoma), myxoid sarcomas (2 liposarcomas and 1 high-grade tumor), round-cell tumors (1 malignant histiocytic tumor and 1 chloroma), osteosarcomas (3), chondrosarcomas (3), and borderline tumors (2 pleomorphic lipoma, 1 myxolipoma, 1 cranial fasciitis, and 1 fibromatosis). Histological correlation and problems in subtyping on both cytologic and histological material are discussed. It is concluded that FNA cytology can be used with high accuracy to diagnose musculoskeletal tumors in rare sites such as the head and neck.

Entities:  

Mesh:

Year:  1999        PMID: 10086236     DOI: 10.1002/(sici)1097-0339(199903)20:3<131::aid-dc4>3.0.co;2-t

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  2 in total

Review 1.  Primary Epithelioid Sarcoma Manifesting as a Fungating Scalp Mass - Imaging Features and Treatment Options. A Case Report and Literature Review.

Authors:  Yonghao Zhang; Tarun Mohan Mirpuri; Chi Long Ho
Journal:  J Radiol Case Rep       Date:  2021-11-01

2.  Dynamic MRI and fine needle aspiration cytology in the evaluation of soft tissue lesions.

Authors:  Hildur Einarsdóttir; Veli Söderlund; Lambert Skoog; Henrik C F Bauer
Journal:  Skeletal Radiol       Date:  2003-06-26       Impact factor: 2.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.